The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of HRT and low-dose tamoxifen in a phase II trial (HOT): Analysis of mammographic density and endometrial thickness.
B. Bonanni
No relevant relationships to disclose
P. Maisonneuve
No relevant relationships to disclose
D. Serrano
No relevant relationships to disclose
C. Varricchio
No relevant relationships to disclose
M. Cazzaniga
No relevant relationships to disclose
M. Lazzeroni
No relevant relationships to disclose
B. Santillo
No relevant relationships to disclose
R. Di Pace
No relevant relationships to disclose
L. Meneghetti
No relevant relationships to disclose
A. Tagliafico
No relevant relationships to disclose
U. Veronesi
No relevant relationships to disclose
A. De Censi
No relevant relationships to disclose